Syndax Pharmaceuticals, Inc. Share Price & Technical Analysis
SNDX · $19.99 (+0.25%)
Healthcare / Biotechnology
$19.99
+0.25%
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-4% return in May, -12% avg return in past 3 year May month.
-3% return in 2026, 12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | 7% | 8% | -10% | -4% | – | – | – | – | – | – | – | -3% |
| 25 | 6% | 13% | -23% | 16% | -26% | -10% | 8% | 65% | -7% | -12% | 46% | 6% | 81% |
| 24 | -4% | 14% | 0% | -11% | -9% | 5% | 11% | -10% | -6% | -1% | -13% | -21% | -45% |
| 23 | 10% | -11% | -14% | -2% | -3% | 5% | 1% | -13% | -23% | 5% | 17% | 29% | 1% |
| 22 | -26% | -5% | 12% | -3% | -1% | 16% | 6% | 16% | 2% | -5% | 4% | 7% | 23% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.83B
P/E ratio
—
52W high
$25.59
52W low
$8.59
Volume
38,948
Beta
0.41
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Syndax Pharmaceuticals, Inc. share price today?
- Syndax Pharmaceuticals, Inc. (SNDX) last traded around $19.99 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SNDX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SNDX. Download the app for real-time alerts.
- How can I analyze Syndax Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.